PDE4A and atopic eczema: After roflumilast, three other PDE4 inhibitors have been approved for clinical use, namely apremilast (Figure 2) for psoriatic arthritis, crisaborole for atopic dermatitis and ibudilast for Krabbe disease [35,36,37,38,39].